Federal Appeals Court Blocks Mailing of Mifepristone, Restricting Abortion Access Nationwide
A federal appeals court has issued a ruling that restricts access to mifepristone, a common abortion pill, by blocking its distribution through mail. The New Orleans-based 5th U.S. Circuit Court of Appeals has mandated that mifepristone can only be dispensed in-person at clinics. This decision follows the Supreme Court's 2022 ruling that overturned Roe v. Wade, which had previously protected abortion rights nationwide. The ruling is expected to be appealed to the Supreme Court. Mifepristone, approved in 2000, is used in combination with misoprostol to terminate early pregnancies. The FDA had initially imposed strict regulations on its distribution due to rare cases of excessive bleeding, requiring in-person prescriptions. These restrictions were lifted during the COVID-19 pandemic, allowing for mail prescriptions. The recent court decision has raised concerns about access to abortion and miscarriage care, particularly affecting rural communities, low-income individuals, and marginalized groups. 
